New-Onset Blepharitis in a Patient Treated With Secukinumab for Severe Psoriasis

New-Onset Blepharitis in a Patient Treated With Secukinumab for Severe Psoriasis

Authors

  • Maria Francesca Baracca Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy. Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Italy
  • Filippo Viviani Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy. Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Italy
  • Alessandro Pileri Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy. Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Italy
  • Giacomo Clarizio Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy . Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Italy
  • Federico Bardazzi Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy

References

Teraki Y, Takahashi A, Inoue Y, Takamura S. Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis. Acta Derm Venereol. 2018;98(4):456-457. DOI: 10.2340/00015555-2871. PMID: 29327064.

Alsenaid A, Piguet V, Lansang P, Miller-Monthrope Y, Yeung J, Joseph M. Brodalumab-Induced Eczematous Reactions in Psoriasis Patients: Management With Switching to Risankizumab. J Cutan Med Surg. 2023;27(3):236-240. DOI: 10.1177/12034754231167140. PMID: 37014149.

Downloads

Published

2024-07-31

Issue

Vol. 14 No. 3 (2024): 2024 Vol 14, No 3 | July

Section

Image Letter

License

Copyright (c) 2024 Maria Francesca Baracca, Filippo Viviani, Alessandro Pileri, Giacomo Clarizio, Federico Bardazzi

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.

How to Cite

1.
New-Onset Blepharitis in a Patient Treated With Secukinumab for Severe Psoriasis . Dermatol Pract Concept [Internet]. 2024 Jul. 31 [cited 2024 Dec. 5];14(3):e2024185. Available from: https://www.dpcj.org/index.php/dpc/article/view/4184

Share

Crossref
Scopus
Google Scholar
Europe PMC